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A B S T R A C T
Adverse drug reactions have been linked with genetic polymorphisms in HLA genes in numerous diﬀerent
studies. HLA proteins have an essential role in the presentation of self and non-self peptides, as part of the
adaptive immune response. Amongst the associated drugs-allele combinations, anti-HIV drug Abacavir has been
shown to be associated with the HLA-B*57:01 allele, and anti-epilepsy drug Carbamazepine with B*15:02, in
both cases likely following the altered peptide repertoire model of interaction. Under this model, the drug binds
directly to the antigen presentation region, causing diﬀerent self peptides to be presented, which trigger an
unwanted immune response. There is growing interest in searching for evidence supporting this model for other
ADRs using bioinformatics techniques. In this study, in silico docking was used to assess the utility and reliability
of well-known docking programs when addressing these challenging HLA-drug situations. The overall aim was to
address the uncertainty of docking programs giving diﬀerent results by completing a detailed comparative study
of docking software, grounded in the MHC-ligand experimental structural data – for Abacavir and to a lesser
extent Carbamazepine - in order to assess their performance. Four docking programs: SwissDock, ROSIE,
AutoDock Vina and AutoDockFR, were used to investigate if each software could accurately dock the Abacavir
back into the crystal structure for the protein arising from the known risk allele, and if they were able to
distinguish between the HLA-associated and non-HLA-associated (control) alleles. The impact of using homology
models on the docking performance and how using diﬀerent parameters, such as including receptor ﬂexibility,
aﬀected the docking performance were also investigated to simulate the approach where a crystal structure for a
given HLA allele may be unavailable. The programs that were best able to predict the binding position of
Abacavir were then used to recreate the docking seen for Carbamazepine with B*15:02 and controls alleles.
It was found that the programs investigated were sometimes able to correctly predict the binding mode of
Abacavir with B*57:01 but not always. Each of the software packages that were assessed could predict the
binding of Abacavir and Carbamazepine within the correct sub-pocket and, with the exception of ROSIE, was
able to correctly distinguish between risk and control alleles. We found that docking to homology models could
produce poorer quality predictions, especially when sequence diﬀerences impact the architecture of predicted
binding pockets. Caution must therefore be used as inaccurate structures may lead to erroneous docking pre-
dictions. Incorporating receptor ﬂexibility was found to negatively aﬀect the docking performance for the ex-
amples investigated. Taken together, our ﬁndings help characterise the potential but also the limitations of
computational prediction of drug-HLA interactions. These docking techniques should therefore always be used
with care and alongside other methods of investigation, in order to be able to draw strong conclusions from the
given results.
1. Introduction
An adverse drug reaction (ADR) is a harmful or unpleasant reaction,
resulting from the use of medicinal products. Type A reactions are those
that are dose-related. Idiosyncratic drug reactions (IDRs) or Type B
hypersensitivity reactions are dose-independent, occurring in some but
not all people (Edwards and Aronson, 2000). The incidence of ADRs has
increased globally from 2.2 million in 1994 to 10 million in 2014
(Vazquez-Alvarez et al., 2017). This is therefore a very important issue
which needs to be addressed.
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These ADRs have been linked with speciﬁc Human Leukocyte
Antigens (HLA) in numerous studies, whereby individuals carrying
particular alleles of HLA genes are at higher risk of developing adverse
reactions to particular drugs (Carr et al., 2013; Tangamornsuksan et al.,
2015; Zhou et al., 2015). HLA gene products play a key role in the
adaptive immune response, presenting peptides (self and non-self) to a
T cell receptor to elicit a response when needed. The HLA system is
highly variable, both in individuals and in populations. Individuals
carry multiple HLA genes with similar functions: A, B, C in class I, or
DRA, DRB, DQA, DQB and others in class II. In general, Class I gene
products are responsible for presentation of peptides from pathogens
internal to cells, such as viruses. Class II gene products present peptides
from extracellular pathogens.
The role of HLA in ADRs has been hypothesised in three main ways.
The Hapten model predicts that the drug binds covalently to a self
protein, and is processed via HLA molecules to the presented peptide;
this drug-protein combination then being recognised as being non-self
and initiating an immune response. The Pharmacological Interaction (PI)
model predicts that the drug binds non-covalently, directly to the im-
mune receptors; mainly T-cell receptors or HLA. The Altered Peptide
Repertoire model states that the drug interacts with the HLA molecule
directly and non-covalently, leading to a diﬀerent self-peptide set being
presented, which is recognised as foreign, and thus eliciting the im-
mune reaction (Yun et al., 2016). Illing et al. showed that the Abacavir
modiﬁes the anchor residue for the binding peptide in the F-pocket,
altering the binding speciﬁcity for peptides in B*57:01 but not B*57:03
(Illing et al., 2012).
ADRs are associated with diﬀerent HLA alleles for numerous dif-
ferent drugs. The ‘HLA and Adverse Drug Reactions’ database on the
Allele Frequency Net Database website (Gonzalez-Galarza et al., 2015;
Ghattaoraya et al., 2016) allows users to search for studies showing
associations between diﬀerent HLA alleles and ADRs. The current, most
strongly associated ADR is that of Abacavir (an anti-retroviral drug)
with HLA-B*57:01. If certain alleles have been signiﬁcantly associated
with ADRs, patients can be screened prior to being given the drug to
predict if an ADR is likely to occur. Mallal et al. showed how screening
for HLA-B*57:01 alleles can reduce the risk of hypersensitivity reac-
tions in patients receiving Abacavir (Mallal et al., 2008). While there is
still some disagreement which of the models best explains how they
interact with drugs to cause ADRs, Illing at al. and Ostrov et al. have
demonstrated the Altered Peptide Repertoire model with high con-
ﬁdence for Abacavir, including a crystal structure of Abacavir bound to
the antigen presenting region of HLA-B*57:01, as well as proteomics
evidence for diﬀerent peptides being presented than in the unbound
case. As a result, many researchers investigating ADRs now work under
the assumption that this hypothesis explains a high proportion of HLA
ADRs observed, although much debate continues. There is therefore
considerable and growing interest in searching for evidence supporting
this mode for other ADRs using modelling and bioinformatics techni-
ques, for example using in silico molecular docking (Illing et al., 2012;
Carr et al., 2017; Van Den Driessche and Fourches, 2017; Wei et al.,
2012; Luo et al., 2015).
Molecular docking is used to predict the preferred orientation of a
molecule when bound to another in a stable complex. Most docking
programs assume the target to be rigid and allow ligand ﬂexibility
(Pagadala et al., 2017). Protein-ligand docking can be used to aid un-
derstanding of biological processes and drug design (Lengauer and
Rarey, 1996; Gaba et al., 2010). Docking gives a prediction of the
structure of the ligand-receptor complex using computational methods
by ﬁrst sampling the conformations of the ligand in the active site and
then ranking these conformations using a scoring function as a proxy
for the free energy of interaction (Meng et al., 2011).
Molecular docking is being used increasingly commonly for in-
vestigating HLA-mediated ADRs (Illing et al., 2012; Carr et al., 2017;
Van Den Driessche and Fourches, 2017; Luo et al., 2015; Goldstein
et al., 2014; Teh et al., 2016; Hirayama, 2017; Schotland et al., 2016;
Isogai et al., 2013; Yang et al., 2015). The HLA structure presents
unusual challenges for molecular docking protocols. HLAs bind pep-
tides in a long hydrophobic cleft formed between the α-helices and β-
sheet platform. This cleft is much larger than the naturally evolved
binding sites that proteins have for small organic molecules. The
polymorphic residues located along this cleft determine the size and
stereochemistry of the subsites (Zeng et al., 1997). The peptide binding
groove contains six subsites (Fig. 1). The speciﬁcity of peptide binding
is determined in part by the interactions between anchor residues on
the peptide side chains and two or more of these subsites (Johansen
et al., 1997). Therefore care must be taken when using docking
methods to investigate these complex cases. The purpose of this ex-
ercise is to compare multiple docking programs to assess their perfor-
mance on the challenging HLA-ADR cases.
Four diﬀerent freely available and commonly used programs were
used for docking the compounds with the target alleles – SwissDock,
ROSIE, AutoDock Vina and AutoDockFR, as follows.
The SwissDock (Grosdidier et al., 2011a) server is an online tool
based on the EADock DSS engine using a multiobjective scoring func-
tion designed around the CHARMM22 force ﬁeld and FACTS solvation
Fig. 1. Organisation of the subsites along the HLA peptide binding groove. The peptide-binding groove of the HLA molecule is separated into 6 diﬀerent pockets
(A–F) (Saper et al., 1991; Sidney et al., 2008), as shown here. Image created using PyMOL (Schrodinger, 2015).
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model (Grosdidier et al., 2011b). Target and ligand structures can be
automatically prepared for docking through the server. Target struc-
tures can be selected via PDB records, or user-deﬁned structures can be
uploaded in various supported formats. Ligands can be selected through
the ZINC database or by uploading structure ﬁles. A range of docking
parameters can be set, including docking type, enabling the user to
select a desired docking time and exhaustiveness, and deﬁning the
search space (Grosdidier et al., 2011a). Due to it being an online tool, it
is very accessible and can be used without the technical knowledge
required for some of the more complex software.
The Rosetta Online Server that Includes Everyone (ROSIE) is an
online version of the Rosetta 3 software. The server includes diﬀerent
Rosetta protocols, including RosettaLigand which allows small mole-
cules to be docked into proteins. The Rosetta energy function approx-
imates the energy of a biomolecule conformation, this is computed as a
linear combination of energy terms (Alford et al., 2017). The target
structure must be provided in PDB format. For best results, residues that
Rosetta does not natively recognise (e.g. waters, co-factors or metal
ions) should be removed prior to submission. An SDF ﬁle containing the
conformers of a single ligand should also be provided. The approximate
location of the binding site should also be speciﬁed, as RosettaLigand
cannot perform binding site detection. Again, multiple parameters can
be selected (Combs et al., 2013; Lyskov et al., 2013).
Finally, two versions of AutoDock were also used, both tools that
can be installed and run locally. AutoDock Vina was shown to be a
strong competitor against six other programs when tested against a
virtual screening benchmark (Trott and Olson, 2010). The latest Au-
toDock software, AutoDockFR was also used. AutoDockFR uses a ge-
netic algorithm and scoring function based on the AutoDock4 scoring
function, whereas AutoDock Vina uses a simpler scoring function. Au-
toDockFR diﬀers from the other programs as it takes into account re-
ceptor ﬂexibility by allowing the user to specify ﬂexible residues within
the target structure, this allows the program to simulate induced ﬁt
caused by ligand binding where changes occur mainly in the residues
side chains. This software was shown to outperform AutoDock Vina for
tested datasets (Ravindranath et al., 2015). For both of the AutoDock
versions, target and ligand structures are to be provided in PDBQT
format. The search space, including the binding site, must also be
speciﬁed with other optional parameters also available. AutoDock is
commonly used for in silico docking of associated drugs with HLA al-
leles. It is therefore important to assess the reliability of the diﬀerent
versions of this program when using the complex HLA structure ex-
amples.
Two drugs were investigated. Abacavir, an anti-retroviral drug used
to suppress HIV replication, is the most widely investigated drug as-
sociating ADRs with HLA. It has been shown that there is a genetic
association between HLA-B*57:01 and Abacavir (Tangamornsuksan
et al., 2015; Mallal et al., 2002; Berka et al., 2012). The ADR is thought
to be driven by the activation of CD8+T cells (Chessman et al., 2008).
The mechanism of Abacavir binding has been experimentally validated
by X-ray crystallography and shown to correspond with the altered
peptide repertoire model. Abacavir binds directly and non-covalently
with the HLA-B*57:01 binding cleft in the F-pocket (Fig. 1) of the
peptide-binding groove (Ostrov et al., 2012). This binding results in an
alteration of the physicochemical parameters and topography of the
binding groove, altering the presented peptides and eliciting a poly-
clonal T-cell response leading to the Abacavir hypersensitivity reaction.
Alterations at key residues within the binding cleft have been shown to
prevent the Abacavir association, by testing closely related allotypes
(e.g. HLA-B*57:03) and comparing the resulting hypersensitivity reac-
tions seen in the risk B*57:01 allele (White et al., 2014).
The second drug investigated was Carbamazepine, an anti-epileptic
drug, which has been strongly associated with Stevens-Johnson syn-
drome / toxic epidermal necrolysis (SJS/TEN), with patients having the
B*15:02 allele showing hypersensitivity (Zhou et al., 2015). It is
thought that the binding of Carbamazepine alters the self-presented
peptides, through direct binding to the HLA molecule, similar to the
Abacavir mechanism. These peptides are then recognised as foreign,
leading to an immune response. Although the binding has not been
experimentally validated, in silico modelling predicted the binding of
Carbamazepine to HLA-B*15:02. It was predicted that the Carbamaze-
pine binds in the D-pocket of B*15:02, adjacent to residue 156 of the
HLA molecule (Illing et al., 2012). This is one of the residues where the
HLA-B*15:01 and HLA-B*15:02 alleles diﬀer. As hypersensitivity is
only seen in patients with the HLA-B*15:02 allele but not HLA-B*15:01,
it is likely that this residue plays an important role in the ADR. A se-
parate study has also predicted the binding site both through site-di-
rected mutagenesis and in silico docking. The results of the site-directed
mutagenesis implicated Asn63, Ile95 and Leu156, found in the D-
pocket, in Carbamazepine presentation and T-cell activation as muta-
tions at these positions (N63E, I95 L or L156W) showed reduced
binding aﬃnity for Carbamazepine. In silico modelling conducted in
the same study showed consistent binding near to the Arg62 residue
located in the D-pocket of the peptide binding groove (Wei et al., 2012;
White et al., 2014). These examples can therefore be used to test if the
docking methods used predict the same binding position shown in these
previous independent studies.
In this work, we used the Abacavir example for which a crystal
structure of the complex exists, as a benchmark for the docking soft-
ware. By using molecular docking, the binding position of the Abacavir
within the B*57:01 risk allele HLA structure and, for comparison, with
the non-risk control allele structures was predicted. Controls were
chosen from B alleles shown to be non-risk (B*57:03) and common
HLA-B and HLA-A alleles (B*07:02 and A*01:01). We work under the
assumption that for (control) alleles that have not been associated with
an ADR, that this is due to the drug not binding suﬃciently strongly to
aﬀect peptide presentation. Illing et al. showed that Abacavir interacts
non-covalently with the B*57:01 risk allele but not with B*57:03 con-
trol (Illing et al., 2012). The docking was completed in the absence of
the peptide. As we are working upon the Altered Peptide Repertoire
model, the Abacavir is thought to be accommodated within the peptide
binding groove, leading to a change in the peptide being presented.
Previous in silico studies suggest that Abacavir can interact with the
B*57:01 F-pocket without the peptide being present (Norcross et al.,
2012; Yang et al., 2009). The docking results were then compared to the
known binding position to estimate the reliability of the docking pro-
tocol. In addition, we assessed to what extent the docking could dis-
tinguish between the HLA-associated and non-HLA-associated alleles.
The same methods were used to test if the Carbamazepine binding
position previously seen can be reliably replicated, using the programs
showing the most accurate results for the Abacavir example. Due to
there being more evidence available for the Abacavir example, in-
cluding a crystal structure of the drug bound in complex, our in-
vestigations favour this example. For the Carbamazepine example, we
are comparing our results against a previous prediction using similar
methods.
This work sheds light on the utility and reliability of well-known
docking programs used to address the challenging HLA-drug situation.
These docking methods may help us to understand the mechanisms
behind ADRs and identify genetic polymorphisms that may be inﬂu-
encing the binding seen in the risk but not control alleles.
2. Methods
2.1. Homology modelling: obtaining target structures
For the Abacavir example, B*57:01 has been shown to be a risk
allele and B*57:03 not associated. For Carbamazepine B*15:02 was
found to be the risk allele, with B*15:01 not being associated. These
non-associated alleles were therefore used as controls along with a
common HLA-B allele (B*07:02) and HLA-A allele (A*01:01) which
could be assumed to not be associated as they are seen at a high
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frequency across European origin (Caucasian) populations (average
frequencies obtained from AFND using gold standard populations
(Gonzalez-Galarza et al., 2015): B*57:01=0.03, B*07:02= 0.10 and
A*01:01= 0.14).
The allele structures were obtained from the PDB database, where
available. Models were made for those alleles where the structure is not
publicly available (Table 1). Target and template sequences were
aligned with ClustalX (Thompson et al., 1997). For each modelling
exercise, ten models were generated using Modeller 9.9 automodel class
and the model with the lowest objective function score was chosen as
the model for docking. This objective function is a score generated from
the spatial restraints and the CHARMM energy terms, reﬂecting ste-
reochemistry within the structure (Sali and Blundell, 1993). In these
simple cases there was no need to explore alternative target-template
alignments since sequences could be aligned unambiguously with no
insertions or deletions.
As there are multiple crystal structures available for B*57:01 in
complex with Abacavir (3VRI (Illing et al., 2012), 3UPR (Ostrov et al.,
2012), 3VRJ (Illing et al., 2012) and 5U98 (Yerly et al., 2017)) these
were compared to ensure there were no major diﬀerences between
docking results using each of the starting structures (Supplementary
Fig. 1). The highest resolution structure (3VRI) was selected to be used
in the docking.
The Abacavir risk and control alleles were used to evaluate the
homology modelling as the known structures are available for each
allele investigated and so can be compared with the model structure
and docking results. Two models were created for B*57:03, one with
one template allele (B5703_m) and another with two template alleles
(B5703_m2). These models could then be compared to the known
structure of B*57:03 (B5703_s), as could the docking predictions, to
understand the inﬂuence of these steps when employed in a typical
docking protocol. The structure of B*57:01 was also modelled
(B5701_m), from two similar sequences identiﬁed to make similar
comparisons and evaluate the reliability of using homology modelling.
For the Carbamazepine risk associated allele B*15:02, there are four
diﬀering residues with control allele B*15:01. Three of these lie in the
peptide binding groove, with only one of these being vital to the D-
pocket architecture, where the Carbamazepine is predicted to bind (pos
156). Only a single template, the structure of B*15:01, was therefore
used to model B*15:02 (B1502_m).
The quality of each model was investigated using Ramachandran
plots and QMEAN scores. For the B5701_m and B5703_ m and m2,
RMSDs (Root-Mean-Square Deviation) were used to give a measure of
how well the models represent the known structures. The percentage
sequence identity for each of the templates used for each model are
shown in Supplementary Table 1.
2.1.1. Conformational sampling of receptor protein structures
In order to identify the ﬂexible side chains for the target structure,
the relax function of Rosetta was used to explore the conformational
properties of each residue. By looking at 10 diﬀerent relaxed structures
for each target, ﬂexible residues can be identiﬁed. This allows us to
consider the ﬂexibility of the target structure when using AutoDockFR.
When using the ROSIE server, a similar sampling is incorporated into
the docking procedures (Lyskov et al., 2013).
2.2. Docking
2.2.1. SwissDock
Using SwissDock (Grosdidier et al., 2011a), the default parameters
search the whole target structure but by setting the search space
parameters, it is possible to restrict binding to perform a local docking
assay using the known binding pocket. Here, the area of interest is the
peptide binding groove, including residues 1–180 of the alpha chain.
The search space was therefore restricted to this area of interest. The
ﬁle was processed to ensure it was in the correct format to be uploaded
to SwissDock. This included removing the ligand and peptide from the
structure. The PDB was then passed through the Prepdock server
(Vriend, 2008) to prepare the structure for docking. This prepared ﬁle
was then submitted to SwissDock with the relevant known drug struc-
tures. SwissDock used the ZINC database to obtain the known structures
of compounds (Abacavir ZINC ID: 2015928, Carbamazepine ZINC ID:
4785). The top 6 poses were used for comparisons.
2.2.2. ROSIE
ROSIE (Combs et al., 2013; Lyskov et al., 2013), was also used in a
similar way. The PDB ﬁles were again prepared, removing the Abacavir
and peptide from 3VRI and this time also removing the water molecules
from the target structure, as Rosetta is unable to natively recognise
these residues. The Abacavir drug structure was extracted from the
relevant PDB (3VRI) and converted to SDF format. This was then sub-
mitted to the server to be docked, with the search space speciﬁed to
centre on the peptide binding groove. This process was repeated for
each of the risk and control alleles to be investigated. The top 10 poses
were used for comparisons.
2.2.3. AutoDock
Two versions of AutoDock were also used, AutoDock Vina (Trott
and Olson, 2010) and the later version AutoDockFR (Ravindranath
et al., 2015). AutoDock Tools (Sanner, 1999) was used to prepare the
PDBQT ﬁles for both the target HLA alleles and the ligand structure.
The drug structures for Abacavir was extracted from the 3VRI PDB ﬁle
(Illing et al., 2012). For Carbamazepine, there is no crystal structure
available for the drug bound to a target and so the PDB ﬁle was ob-
tained from the ZINC entry previously used for the SwissDock docking
and from the Drugbank structure.
Using AutoDock Vina, a search space of 40× 40×40 Å was used.
Initially, the default exhaustiveness was used but this was then in-
creased gradually to identify the best parameters to ﬁnd the closest
docking poses of Abacavir to the native position seen in the crystal
Table 1
Structures of risk and control HLA alleles used in docking experiments. To distinguish between crystal structures and those created by homology models in the rest of
the text, we add labels with suﬃx “sN” and “mN” where s means crystal structure and m means homology model, N is an integer where multiple models have been
created.
Drug Risk Allele Risk Allele Structure Control Allele Control Allele Structure
Abacavir B*57:01 3VRI (Illing et al., 2012) (B5701_s) B*57:03 2BVP (Stewart-Jones et al., 2005) (B5703_s)
Homology model using B*52:01 (3W39 (Yagita et al., 2013)) and B*58:01 (5IM7
(Li et al., 2016)) as templates (B5701_m)
Homology model using B*57:01 as a
template (B5703_m)
Homology model using B*57:01 and B*07:02
(B5703_m2)
2RFX (Chessman et al., 2008) (B5701_s2) B*07:02 4U1H (Kloverpris et al., 2015) (B0702_s)
A*01:01 3BO8(Sato et al., 2011) (A0101_s)
Carbamazepine B*15:02 Homology model using B*15:01 as template (B1502_m) B*15:01 1XR9 (Roder et al., 2006) (B1501_s)
B*07:02 4U1H (Kloverpris et al., 2015) (B0702_s)
A*01:01 3BO8 (Sato et al., 2011) (A0101_s)
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structure. Once this was identiﬁed, the process was then repeated for
the other alleles, using the same parameters. For AutoDock Vina, the
predictions are clustered to give 9 poses which were used for compar-
isons.
Using AutoDockFR, the docking was performed twice, either as-
suming the target as rigid or allowing for ﬂexible residues. The aligned
alleles and the ligand PDB ﬁles were converted to PDBQT ﬁles using
AutoDock Tools (Sanner, 1999). The target structure and ligands were
then loaded separately into AutoGridFR (Sanner et al., 1996). The
pockets located within the target structure were identiﬁed and the
search space selected to 1) surround the known binding position of the
ligand, 2) surround the peptide binding groove and 3) surround the top
three largest pockets identiﬁed. By selecting the top three pockets, this
increases the search space and gives the opportunity for the ligand to
bind in an alternative pocket and can tell us if the peptide binding
groove is indeed the favoured binding region or not. The aﬃnity maps
are then generated by AutoGridFR and these are then inputted into
AutoDockFR along with the ligand and the parameters for the docking.
This process was repeated for each of the alleles, using the three dif-
ferent search spaces. As AutoDockFR only gives the binding pose for the
top binding solution, AutoDockFR was ran in batches in order to obtain
multiple binding poses. The top pose is therefore given for a selection of
ten runs as opposed to the top poses for one run, as seen in the other
examples.
Rosetta Relax was used to identify ﬂexible side chains. These re-
sidues were then selected as ﬂexible in AutoGridFR and the search
space was set along the peptide binding groove, encompassing these
residues. The aﬃnity maps were generated and as before, inputted into
AutoDockFR.
It was predicted that AutoDockFR may show more accurate docking
predictions for unbound structures than those using the 3VRI crystal
structure with both Abacavir and the peptide removed. As a result, the
structure of HLA-B*57:01 without Abacavir bound (B5701_s2) was
obtained from the PDB database (2RFX (Chessman et al., 2008)). The
peptide bound was removed and the B*57:01 structure was used in a
similar way to give predicted binding when searching the peptide
binding groove, assuming the receptor to be either rigid or ﬂexible.
The results ﬁles from all the docking programs were then processed.
The RMSDs between the non-hydrogen atoms of the docked poses and
the known binding position of Abacavir were calculated through
PyMOL (Schrodinger, 2015) using the “rms_cur” command. RMSDs
were used to give a quantitative guide to how close the prediction poses
lay to the known binding mode of Abacavir. The RMSDs along with
visual inspection and docking scores were used to assess the reliability
of each of the docking programs. The scores were also used to in-
vestigate the relationship between the binding scores and positions. The
binding predictions for Carbamazepine were compared to predictions
from previous studies in a similar way although RMSDs could not be
measured for that case as no crystal structure was available.
3. Results
3.1. Homology modelling
The ﬁrst analysis was to explore the overall eﬀect of homology
modelling on the reliability of results from in silico docking. As ex-
pected, given the small number of amino-acid diﬀerences between
models and templates, the QMean and Ramachandran plots for each of
the alleles were shown to be within acceptable limits, showing the
models to be of good quality. B5701_m was shown to be very similar to
the known structure B5701_s with RMSD 0.81 Å (266 to 266 atoms).
The B*57:03 models also showed low RMSDs (B5703_m=1.46 Å (266
to 266 atoms), B5703_m2=1.24 Å (266 to 266 atoms)) when com-
pared to the known structure B5703_s. The two diﬀering residues be-
tween the B*57:03 and B*57:01 alleles (position 114 and 116) both lie
along the peptide binding groove and are vital for the architecture of
the F-pocket shown to be the known binding position of Abacavir. It is
therefore important that the model correctly represents the allele
structure. When comparing the B*57:03 and B*07:02 control allele
structures used for the Abacavir example with B5701_s, it could be seen
that the tyrosine at position 116 for the B*57:03 and B*07:02 known
structures overlaps with the known binding position of the Abacavir. It
would be expected for the tyrosine in the B*57:03 model to show a
similar conformation to that seen in these known structures. This was
not seen in the B5703_m model but was seen in the B5703_m2 model in
which two templates were used (Supplementary Fig. 2). Using two
templates for the model gave a more accurate representation of this
element of the target structure in this case.
Fig. 2. Binding positions for B*57:01
(B5701_s1) with Abacavir using SwissDock
(a–c) and AutoDockFR (d–f). Predicted
Abacavir binding positions using SwissDock
(a–c) and AutoDockFR (d–f) are shown by
white molecules with B5701_s1 shown as grey
structure. The known binding position of
Abacavir is shown as mesh. (a) All binding
poses using SwissDock, (b) SwissDock pose 1
giving lowest RMSD of 2.02 Å and (c)
SwissDock pose 4 giving a higher RMSD of
6.92 Å due to reversed orientation, (d) All
binding poses using AutoDockFR, (e)
AutoDockFR pose 3 giving lowest RMSD of
2.25 Å and (f) AutoDockFR pose 5 giving a
higher RMSD of 6.92 Å due to reversed or-
ientation. AutoDockFR docking ran using the
search space centred on the known binding
position of the ligand.
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3.2. Abacavir
3.2.1. All docking software assessed could dock Abacavir into the risk allele
crystal structure but could not always predict the correct binding mode
The success of the docking programs was determined by how ac-
curately each program could re-create the known binding position of
Abacavir. This was completed using a combination of visual inspection
and using RMSD as a quantitative measure between the known and
predicted poses. Using SwissDock, it can be seen that the B5701_s ex-
ample gives a docking solution close to the native position (Fig. 2a-c)
with all poses showing binding in the F-pocket. When using Auto-
DockFR assuming the receptor to be rigid, similar results were seen to
those using SwissDock (Fig. 2d-f). All poses for the B5701_s risk allele
were shown bound in the same pocket as the known binding position.
Little diﬀerence was seen between the docking shown for each search
space, with only one pose from the B*57:01 run showing binding out-
side of the peptide binding groove when the search space was extended
around the whole protein (data not shown). This indicates that the
peptide binding groove is the most favourable region for binding. It can
be concluded overall that the Abacavir docks in the expected binding
pocket for these packages, but they cannot predict the exact native
pose.
As the ROSIE server allows movement of side chains within the
target, the modelled structure of the B*57:01 risk allele target was
compared to the B5703_s structure submitted. This resulted in the
RMSDs shown in Table 2 with B5701_s giving similar average RMSDs to
the control alleles. Comparing the lowest RMSDs, the control structures
give poses with lower RMSDs than B5701_s.
For AutoDock Vina, exhaustiveness is shown in brackets as (exh=).
The lowest and highest RMSDs are shown along with the averages for
all poses, pose rank is shown in brackets. (For SwissDock, poses are
ranked from 0-5. For ROSIE and AutoDock Vina, poses are ranked from
1-9. Rank is not shown for AutoDock FR, as each pose was taken from
top pose for each of 10 runs). Search spaces include surrounding the
peptide binding groove (PBG), surrounding around the known ligand
binding position (Ligand) and surrounding the top three largest binding
pockets to increase the search space to enable binding away from the
peptide binding groove (Top 3).
When docking the Abacavir structure using AutoDock Vina, the
exhaustiveness was investigated using the B*57:01 example (B5701_s)
to optimise the protocol before docking the other non-risk alleles. Using
the default exhaustiveness of 8, the RMSD values were shown to be
quite variable (Table 2). The exhaustiveness was then increased starting
at exh= 18 and doubling the exhaustiveness to see the eﬀect. It was
found that the exhaustiveness of 112 gave the lowest RMSDs overall
and these did not improve with further increasing of exhaustiveness.
In order to compare between the docking software, the predicted
binding aﬃnity was calculated for each of the B*57:01_s predicted
poses, using the CSM-lig server (Pires and Ascher, 2016). This could
then be used, alongside RMSD, to investigate how well the software can
predict the known binding position. It was seen that those poses with
the lowest RMSD have the higher predicted binding aﬃnity for each of
the software, excluding ROSIE, showing the poses closest to the known
binding position to be the most favourable. SwissDock and AutoDockFR
showed the strongest correlation between RMSD and Aﬃnity (Supple-
mentary Fig. 3). The closest individual pose to the crystal structure,
from AutoDock Vina, has the highest predicted aﬃnity.
3.2.2. Most docking software assessed can distinguish between risk and
control alleles
Two methods were used to investigate if the docking software can
distinguish between the risk alleles. RMSD values, alongside some vi-
sual inspection, were used to give a measure of how similar the docking
prediction results are to the known binding position obtained from the
crystal structure. Docking scores were also investigated to see if there is
more favourable binding seen in the risk alleles compared to theTa
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controls and also how the scores diﬀer between the predicted poses for
the risk allele itself.
Using RMSDs, it can be seen from Fig. 3 and Table 2 that most of the
software, excluding “AutoDockFR (Ligand)” and ROSIE, showed lower
RMSD’s for B*57:01 than the other control alleles investigated and were
able to distinguish between the known risk allele structure (B5701_s)
and the known control allele structures (B0702_s and B5703_s). Auto-
DockFR using a search space surrounding the known binding position of
the Abacavir ligand, “AutoDockFR (Ligand)”, shows lowest median
RMSD’s for B*07:02. ROSIE shows lowest median RMSD’s for all the
alleles investigated. AutoDock Vina (with exhaustiveness 112) was able
to achieve the lowest RMSD overall for B*57:01 (0.98 Å) but showed
more variability between poses, giving a higher average RMSD, al-
though this was still lower than the average RMSDs for the control al-
leles. Using SwissDock and AutoDockFR, the control alleles showed
higher RMSDs than the risk B*57:01 allele although it can be seen that
some poses gave higher RMSDs, similar to those seen for the control
alleles. Some of the predicted poses for the B*57:01 allele were shown
to be binding in the correct pocket but gave a higher RMSD due to the
reversed orientation (Fig. 2c & f). By examining these poses it can be
seen that the ligand makes similar interactions to the correct binding
pose (Supplementary Fig. 4) but the reversed orientation results in the
higher RMSD. It is therefore important to consider both the poses and
the RMSD scores when comparing binding results.
Fig. 4 shows the docking poses for the control alleles using Swiss-
Dock. It can be seen that the Abacavir binds further from the known
binding position from 3VRI, with A*01:01 showing the largest diﬀer-
ence from the B*57:01 allele, predicting binding away from the peptide
binding groove (RMSDs: lowest= 21.44 Å, average= 23.23 Å,
highest= 25.47 Å).
It can be seen that B*57:01 generally had a lower average RMSD
than the control alleles for all software, excluding ROSIE, even with
these reversed orientations discussed, with the lowest RMSD being
constantly lower than those seen for the controls. Both control alleles
B*57:03 and B*07:02 contain a tyrosine at position 116, rather than the
serine seen in the risk allele, with A*01:01 having an aspartic acid at
position 116. This residue is sensitive for the F-pocket architecture as it
lies along the base of the pocket (Pichler, 2007) and so this mutation
Fig. 3. Boxplots to show RMSD values of Abacavir poses with respect to the known structure. Plots grouped by (a) Allele and (b) software. Search spaces for
AutoDockFR are shown in brackets and include surrounding the peptide binding groove (PBG), surrounding around the known ligand binding position (Ligand) and
surrounding the top three largest binding pockets to increase the search space to enable binding away from the peptide binding groove (Top 3). For AutoDock Vina,
exhaustiveness is shown in brackets.
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prevents binding in this native position.
The full ﬁtness scores for SwissDock poses were investigated, with
lower scoring poses being more favourable than higher scoring poses.
Scores were compared between B*57:01, B*57:03 and B*07:02, it was
found that poses for the B*57:01 risk allele scored more poorly than
those for the non-risk alleles (Fig. 5a), with the control alleles showing
lower scores than the risk allele. This implies that comparison of scores
between alleles is not valid since better docking results were seen for
the risk allele. Put another way, the docking scores were not able to
distinguish between the risk and control alleles. Nevertheless, the
scores for the B*57:01 risk allele are a good guide to pose accuracy, as
there is a modest positive correlation between RMSD and score
(Fig. 5b), with an R2 value of 0.65. Similarly, scores were also in-
vestigated for the other programs used. Although each program uses
diﬀerent scoring functions, none of these were able to distinguish be-
tween risk and control alleles.
3.2.3. Docking performance can be degraded by using a homology model
The docking of Abacavir with the known and modelled structures of
B*57:01 and B*57:03 were compared (Supplementary Fig. 5). This
Fig. 4. All docking poses of Abacavir for control alleles using SwissDock. (a) B*57:03 using one template (B5703_m), (b) B*57:03 using two templates (B5703_m2), (c)
B*07:02 (B0702_s) and (d) A*01:01 (A0101_s). Known binding position of Abacavir shown as mesh. Poses can be seen further from the native pose than found in the
risk allele docking.
Fig. 5. Full ﬁtness scores versus RMSD. (a) Scatterplot to show the full ﬁtness scores vs RMSDs for each pose for each of the diﬀerent alleles. The non-risk allele poses
have lower scores than poses for the risk allele. (b) Scatterplot to show full ﬁtness score vs RMSD for B*57:01 poses.
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allowed us to compare the docking positions between known and
modelled structures. B5701_m showed an unexpected overlap between
the Ser116 residue and the known binding position on Abacavir from
3VRI. This prevented the docking from predicting the exact native pose.
However, poses were still predicted within the F-pocket and had lower
RMSDs seen than those predicted for the non-risk alleles. This slight
diﬀerence between the modelled and known structures may be due to
the peptide bound in the peptide binding groove of the 3VRI structure.
The docking of Abacavir to the known structure of the control allele
B5703_s showed similar results to the modelled structures, with poses
seen away from the known Abacavir binding position and higher
RMSDs (Supplementary Fig. 6). The average RMSDs seen with the
B*57:03 known structure were higher than those seen with the
homology models, showing the Abacavir docks further from the known
binding position with the known structure.
3.2.4. Receptor ﬂexibility negatively aﬀects the docking performance
When the ﬂexible residues were incorporated for the 3VRI docking
with Abacavir example, poses occupied the whole peptide binding
groove and did not favour the F-pocket as expected (Fig. 6). When the
scores for the poses found inside the F-pocket were compared to those
found outside the F-pocket, it was also seen that these scores did not
favour the F-pocket (data not shown). Thus, although the complex al-
gorithms developed for AutoDockFR have been shown to improve the
success of docking (Ravindranath et al., 2015) in general, they de-
graded performance in our example, suggesting that they should only
be used with caution for HLA docking.
3.2.5. Using AutoDockFR cannot compensate for the added diﬃculty of
docking to the unbound target
AutoDockFR was also used to dock Abacavir with the unbound
structure of HLA-B*57:01 (2RFX (Chessman et al., 2008)), crystallised
in the absence of drug, in order to test the possibility that the structure
without Abacavir bound would yield better docking results when ﬂex-
ibility of residues was considered. The peptide was removed from 2RFX
and the B*57:01 structure was used as the target. Again, two runs were
completed, assuming the receptor to be either rigid or ﬂexible.
Docking to the structure assuming rigid side chains produced poses
in both the B and F pockets (Fig. 7a). However, the lowest RMSD is seen
as 8 Å and is therefore not very accurate when comparing to the known
binding position. When looking at the poses, it can be seen that the
native pose could not be predicted. When ﬂexible residues were in-
corporated with AutoDockFR (Fig. 7b), the entire peptide binding
groove was again occupied.
The poorer docking predictions seen with the B*57:01 structure
without the drug bound could be due to diﬀerences of side chain con-
formation within the peptide binding groove caused by the diﬀerent
peptides and the absence of the drug being bound within the crystal
structure. When comparing these structures, these were shown to be
very similar with RMSD of 0.293 Å (329 to 329 atoms). However, some
diﬀerences can be seen with conformation of side chain residues close
to the known binding of Abacavir, which may aﬀect binding predictions
(Supplementary Fig. 7).
Although AutoDockFR gives good results for the ideal case when
docking the Abacavir structure back into the B*57:01 structure ob-
tained from 3VRI (by removing both the ligand and the peptide), it is
shown here that docking using the unbound structure, crystallised in
the absence of the drug, showed less accurate results and the correct
binding position could not be identiﬁed. This highlights the diﬃculties
of using docking to investigate these challenging HLA-ADR cases as in
general docking for new ADRs will be performed, for example, on
structures that have a peptide already bound but not the drug that is to
be docked.
3.3. Carbamazepine
Although all programs were able to correctly predict the correct
binding pocket for Abacavir, ROSIE was unable to distinguish between
risk and control alleles. AutoDock Vina also showed more variability in
the pose predictions than the other programs. SwissDock and
AutoDockFR also have advantageous features; AutoDockFR is able to
deal with binding site ﬂexibility (Ravindranath et al., 2015) whereas
SwissDock combines user accessibility with the algorithmically ﬂexible
and accurate EADock (Grosdidier et al., 2011a, b). These two programs
were therefore selected as those best able to recreate the binding po-
sitions of Abacavir and were therefore used to predict the binding po-
sition of Carbamazepine with both the risk allele (B1502_m) and the
control alleles (B1501_s, A0101_s and B070_s2). The predicted poses
were compared to those shown in previous studies in which B*15:02
showed binding in the D-pocket, close to residues 62, 63, 95 and 156
(Illing et al., 2012; Wei et al., 2012).
Fig. 6. Abacavir docked with B*57:01 structure (3VRI), using ADFR assuming
the receptor to be ﬂexible. Poses are seen along the whole groove and not just
the F-pocket (shown as surface). The docking is unable to predict the native-like
poses (known binding of Abacavir shown as mesh).
Fig. 7. Abacavir docked with unbound
B*57:01 structure (2RFX), using ADFR. (a)
Assuming the receptor to be rigid. Only a few
poses can be seen bound within the F-pocket
(shown as surface), with these poses showing
incorrect conformation. The docking was un-
able to predict native-like poses (known
binding of Abacavir shown as mesh). (b)
Assuming the receptor to be ﬂexible. Poses are
found along the whole groove and not just the
F-pocket (shown as surface). The docking is
unable to predict the native-like poses (known
binding of Abacavir shown as mesh).
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Docking Carbamazepine with B1502_m using SwissDock, the poses
were predicted to sit in the D-pocket previously identiﬁed as of interest.
Looking at the docking results (Fig. 8a), it can be seen that Carbama-
zepine is predicted to bind in the D-pocket of B*15:02, close to Leu156,
identiﬁed by the study as important, with only one pose predicted out
of this pocket. Using AutoDockFR, the same general pattern was seen
with the D-pocket generally being favoured for B*15:02 (Fig. 8b). Using
SwissDock, the B*15:01 docking showed poses predicted to bind else-
where, away from this pocket, as predicted. For the B*15:01, A*01:01
and B*07:02 alleles, with a mutation at this 156 position (Leu→Trp,
Leu→Arg and Leu→Arg respectively), this D-pocket is closed oﬀ and
produces poses elsewhere (Supplementary Fig. 8). Using AutoDockFR,
the same general pattern was seen with no poses being found in or
around the D-pocket for B*15:01. These predictions cannot be validated
since there is, as of yet, no crystal structure available for Carbamaze-
pine bound to HLA. However, when compared to previous studies, our
results showed a similar binding position using diﬀerent software.
4. Discussion
The purpose of this exercise was to compare multiple docking pro-
grams to assess their performance with these challenging HLA-ADR
cases. We used the Abacavir example as the benchmark for the docking
software, as the crystal structure is available for Abacavir bound in
complex with its associated risk allele. We used the diﬀerent docking
programs to re-dock the Abacavir into the risk allele and measure how
accurately each program could predict the known binding position. It
was found that the binding modes can sometimes be predicted but not
always. Each docking program used was able to predict the Abacavir
binding within the F-pocket and, with the exception of the ROSIE
server, was also able to distinguish between the risk and control alleles
with the best scoring poses for the control alleles being seen further
from the known binding position and in some cases, away from the F-
pocket. This was also generally reﬂected in the RMSDs, although it is
important to consider these alongside the poses themselves as reversed
orientations can give higher RMSDs for poses found close to the known
binding position.
Using the same docking methods to investigate the Carbamazepine
example, the docking programs used were able to recreate previously
published predictions. The docking software was also able to distin-
guish between the risk and control alleles with the risk allele showing
binding in the D-pocket and the other control alleles showing poses
away from the D-pocket.
Here we also investigated the impact of homology modelling on the
docking performance. Homology models are commonly used for
docking, especially with in silico database screening and have been
shown to give accurate docking predictions (Bordogna et al., 2011; Fan
et al., 2009; Ferrara and Jacoby, 2007; Hillisch et al., 2004). However,
localised errors can still have a big impact and so special caution should
be used when there is no crystal structure available for the docking. It is
important to ensure the models are as accurate as possible in order to
give accurate predictions. Especially when mutations may impact the
architecture of the predicted binding pocket, such as in the Abacavir
example.
Predictions of docking poses have subsequently been experimentally
validated by a crystal structure. Yang et al. (2009) predicted binding of
Abacavir to B*57:01 in the F-pocket and predicted positions 114 and
116 as important for binding. This was then conﬁrmed once the crystal
structure of the HLA-drug complex was determined (Illing et al., 2012).
Other predictions have also been made which ﬁt well with experimental
data, about binding of Carbamazepine, for example, where the pre-
dicted binding mode has been shown to be in accord with the experi-
mental data (Zhou et al., 2015).
Caution is needed to overcome the challenges produced from
docking with the HLA structures. The long hydrophobic peptide-
binding cleft is separated into subsites and small molecules can bind in
any of these subsites along the cleft. The binding of drugs to HLA is
probably weaker than many natural and drug-target interactions as the
HLA binding site has not naturally evolved to recognise the drug, nor
has the drug been designed or discovered in a structure-based fashion.
This presents challenges for docking as there may be fewer interactions
formed and less steric complementarity between the drug and its HLA
recognition site. A further complication is the possibility that bound
peptides may stabilise drug poses that would not otherwise be en-
ergetically favourable. Addressing this issue computationally is beyond
the capability of current tools but the possibility should be borne in
mind.
Furthering our understanding of the potentials and limitations of
docking small molecules to HLA is important to aid our understanding
of the underlying mechanisms involved with these ADRs.
Understanding these mechanisms and how the binding of small mole-
cules varies between risk and control alleles may enable us to make
predictions of potential ADRs by identifying polymorphisms which may
contribute to direct binding. This may also lead to improved under-
standing and predictions of ADRs, ultimately leading to reduced risk
due to screening procedures.
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Fig. 8. Docking Carbamazepine with B*15:02 risk allele using SwissDock and AutoDockFR. (a) SwissDock and (b) AutoDockFR poses for Carbamazepine docked with
B*15:02 risk allele. Residue at 116 labelled, with other D-pocket residues shown as mesh.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.molimm.2018.08.003.
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